TWiV 972: Clinical update with Dr. Daniel Griffin - podcast episode cover

TWiV 972: Clinical update with Dr. Daniel Griffin

Jan 07, 202342 minEp. 972
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case.

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
TWiV 972: Clinical update with Dr. Daniel Griffin | This Week in Virology podcast - Listen or read transcript on Metacast